12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ceplene histamine dihydrochloride cancer data

A meta-analysis of data from 1,455 AML patients in first complete remission in 6 international trials showed that IL-2 alone did not significantly increase LFS or OS vs. standard of care (p=0.52 and p=0.46, respectively). Additionally, there was no statistical difference in IL-2 vs. controls in a subset analysis of age, sex, baseline performance,...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >